MCKHealthcare · Medical DistributionThe 16 Wall Street analysts covering McKesson Corp. hold a median 12-month price target of $1,019 — -5.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 5 Nov 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores McKesson Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (99): The share price has been relatively steady.
Accruals (57): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on MCK, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −5.0% from it.
Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Oct 2026 | Mizuho | Maintains | Neutral | $905 → $1,020 |
| 16 Oct 2026 | UBS | Maintains | Buy | $1,080 → $1,200 |
| 7 Oct 2026 | Leerink Partners | Maintains | Outperform | $1,030 → $1,070 |
| 7 Oct 2026 | Leerink Partners | Maintains | Outperform | — |
| 14 Sept 2026 | RBC Capital | Reiterates | Sector Perform | — |
| 14 Sept 2026 | RBC Capital | Reiterates | Sector Perform | $845 |
| 19 Aug 2026 | Barclays | Maintains | Overweight | — |
| 19 Aug 2026 | Barclays | Maintains | Overweight | $925 → $1,000 |
| 19 Aug 2026 | RBC Capital | Initiates | Sector Perform | — |
| 19 Aug 2026 | RBC Capital | Initiates | Sector Perform | $845 |
| 11 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $812 → $933 |
| 11 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 6 Aug 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 6 Aug 2026 | Evercore ISI Group | Maintains | Outperform | $860 → $1,000 |
| 6 Aug 2026 | TD Cowen | Maintains | Buy | $989 → $1,006 |
| 6 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 6 Aug 2026 | UBS | Maintains | Buy | — |
| 6 Aug 2026 | UBS | Maintains | Buy | $1,050 → $1,080 |
| 24 July 2026 | Citigroup | Maintains | Buy | $945 → $1,000 |
| 24 July 2026 | Citigroup | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MCK appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 5 Nov 2026, McKesson Corp. returned +27.5% against +9.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 27% of US stocks
Cheaper than 87% of US stocks
Cheaper than 99% of US stocks
Cheaper than 16% of US stocks
Higher than 47% of US stocks
Higher than 20% of US stocks
Higher than 6% of US stocks
Higher than 47% of US stocks
Higher than 50% of US stocks
Higher than 3% of US stocks
Higher than 75% of US stocks
Higher than 64% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
McKesson Corp. has a market value of $125.0B and an enterprise value of $134.3B.
Revenue in the twelve months to 30 June 2026: $411.0B. The latest quarter grew 7.7% year on year.
Net income over the same four quarters: $5.3B, a 1.3% net margin.
Diluted earnings per share, trailing twelve months: $37.37.
Free cash flow in the twelve months to 30 June 2026: $6.1B, after $271.0M of capital spending.
McKesson Corp. spent $6.7B on share buybacks and $393.0M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 27.7×; forward P/E: 21.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.35%, paying out 9% of earnings.
McKesson Corp. employs 41,600 people — $9.9M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| MCKMcKesson Corp. | $125.0B | 93 |
| CORCencora, Inc. | $64.8B | 77 |
| CAHCardinal Health, Inc. | $62.0B | 98 |
| HSICHenry Schein, Inc. | $9.8B | 82 |
| SYKStryker Corp.* | $128.1B | 71 |
| BMYBristol Myers Squibb Co.* | $128.5B | 95 |
| MDTMedtronic Plc* | $134.4B | 89 |
* Nearest Healthcare names by size — few medical distribution companies of this scale trade in the US universe.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own McKesson Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
McKesson raised its fiscal 2027 earnings outlook following strong second-quarter results. The excerpt attributes the results to specialty drug demand, operating gains, and expansion in higher-margin healthcare.
Why it matters — The raised outlook and cited specialty growth and operating gains are relevant to investors following McKesson’s business performance.
Bristol Gate’s U.S. equity portfolio review said Microsoft was its largest contributor in Q3 2026, while KLA and Applied Materials were the largest detractors. The portfolio bought Garmin, sold Verisk, and rebalanced outliers toward approximately equal weights.
Why it matters — The excerpt discusses portfolio changes and performance but does not mention McKesson, so it offers no specific information about MCK.
McKesson’s second-quarter fiscal 2027 earnings beat estimates, supported by specialty growth and higher prescription volumes. The company raised its guidance despite an after-hours stock dip.
Why it matters — The results and raised guidance provide MCK watchers an update on the company’s performance and outlook.
The source identifies a Seeking Alpha transcript of McKesson Corporation’s Q2 2027 earnings call; the provided excerpt contains no further call details.
Why it matters — MCK watchers are alerted to the availability of the company’s quarterly earnings-call transcript, but no performance or outlook information is included in the excerpt.
Zacks says McKesson’s headline results for the quarter ended September 2026 provide insight into its performance, and notes that key metrics can be compared with Wall Street estimates and year-ago actuals.
Why it matters — Those comparisons offer MCK watchers additional context for assessing the quarterly results.
The 16 Wall Street analysts covering McKesson Corp. have a median 12-month price target of $1,019, with estimates ranging from $845 to $1,207. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering McKesson Corp., 13 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks McKesson Corp. 93 out of 100 across roughly 4,600 US stocks as at 5 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 5 Nov 2026, McKesson Corp. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies -5.0% from the last close, and Ticker Nerd's factor model ranks McKesson Corp. 93 out of 100 as at 5 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering McKesson Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MCK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $845 to $1,207 over the next 12 months.
McKesson Corp. returned +27.5% over the 12 months to 5 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
McKesson Corporation is a healthcare services company that supports the movement of medicines, medical supplies, and related services across the healthcare system. McKesson Corporation serves pharmacies, hospitals, long-term care facilities, clinics, and other care providers through its pharmaceutical distribution, medical-surgical, oncology, and prescription technology businesses.
The most recent item we track (Zacks Investment Research, 5 Nov 2026): "MCK Q2 Earnings Call Highlights Raised Outlook and Specialty Growth". McKesson raised its fiscal 2027 earnings outlook following strong second-quarter results. The excerpt attributes the results to specialty drug demand, operating gains, and expansion in higher-margin healthcare.
McKesson Corporation is a healthcare services company that supports the movement of medicines, medical supplies, and related services across the healthcare system. McKesson Corporation serves pharmacies, hospitals, long-term care facilities, clinics, and other care providers through its pharmaceutical distribution, medical-surgical, oncology, and prescription technology businesses. Its North American Pharmaceutical operations handle branded, generic, specialty, biosimilar, and over-the-counter products, while its Prescription Technology Solutions segment helps connect patients, pharmacies, payers, and biopharma companies through software-enabled workflows. The company’s Medical-Surgical Solutions business supplies healthcare organizations with equipment, consumables, and logistics support. Based in Irving, Texas, McKesson Corporation plays a central role in healthcare infrastructure by helping customers manage access, distribution, and operational efficiency across the care continuum.
CEO Mr. Brian S. Tyler Ph.D. · 41,600 employees · United States · https://www.mckesson.com
